Forum Discussion
Emma17
6 years agoMember
'Lancet Oncology' (May 2019) on denosumab's (Prolia) benefit for reducing bone fracture risk but little evidence for survival benefit: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30146-9/fulltext